April 2008

New England Research Institutes Partners With Evidence

Monday, April 28, 2008

Watertown, Mass.-based CRO New England Research Institutes (NERI) established a strategic partnership with Evidence Clinical and Pharmaceutical Research Institute, a CRO which focuses on conducting trials in Russia and Eastern Europe. Evidence is headquartered in Saint-Petersburg, Russia, and has offices in Los Altos, Calif., and Swampscott, Mass. The companies stated that both Eastern Europe and Russia are becoming increasingly popular regions for conducting clinical trials, and sponsors are creating an ever larger presence there.

[Read More]

Magic Johnson—Celebrity Spokesperson for Minority Patient Recruitment?

Friday, April 18, 2008

Earvin “Magic” Johnson, NBA champion and chairman and chief executive officer of the Johnson Development Corp., came to IIR’s 17th Annual Partnerships with CROs in Las Vegas, Nevada, with a mission—to urge pharma to increase minority participation in clinical trials. But, he left, quite possibly, with an even bigger mission—to become a celebrity spokesperson for minority patient recruitment.

[Read More]

Coast IRB Receives FDA Warning Letter

Tuesday, April 15, 2008

Coast IRB, an independent institutional review board (IRB) based in Colorado Springs, Colo., received a Warning Letter from the U.S. Food and Drug Administration (FDA) concerning the company’s improper expedited review of a phase I study being conducted in northern California. In an unusual move, the agency has temporarily suspended the IRB’s ability to do expedited reviews.

[Read More]

Suven Teams up With Chinese CRO VPSCRO

Friday, April 11, 2008

Asian Clinical Trials (ACT), the CRO of Hyderabad, India-based pharmaceutical company Suven Life Sciences, has entered into a pact with the Beijing -based company VPSCRO to conduct clinical trial services in India and China. VPSCRO claims it is the largest Chinese CRO in term of numbers of ongoing trials. The companies stated that the agreement will provide cost-effective services with faster patient recruitment speeds in the two regions.

[Read More]